Expert Interview
Examining the potential of Ultragenyx's DTX401 Phase 3 Trial Results in treating Glycogen Storage Disease Type Ia (GSDIa)
Ticker(s): RAREInstitution: Self employed
- Pediatric Endocrinologist & Consultant for rare disease trials and former Director of the Glycogen Storage Disease Program at Boston Children's.
- Led the submission of the IND for gene therapy for NGLY1 deficiency, and remains a consultant for rare disease trials.
- Served as the medical lead or the primary consultant for 7 successful IND submissions.
The Phase 3 GlucoGene study reported a statistically significant reduction in daily cornstarch intake with DTX401. Can you explain the clinical importance of this reduction for GSDIa patients?
Added By: catalin_adminOne of the key outcomes was the maintenance of glucose control while reducing cornstarch intake. How does DTX401 achieve this balance, and what does it mean for the daily management of GSDIa?
Added By: catalin_adminThe study also met secondary endpoints, including a reduction in the number of daily cornstarch doses. How might these reductions affect the quality of life for patients and their families?
Added By: catalin_adminDTX401 demonstrated an acceptable safety profile with manageable hepatic effects. What are the main safety concerns with gene therapy in GSDIa, and how were they addressed in this study?
Added By: catalin_adminThe Patient Global Impression of Change (PGIC) showed varying degrees of improvement. How do these subjective measures correlate with the objective findings, and what do they tell us about the patient experience?
Added By: catalin_adminGiven the durable response observed in the Phase 1/2 study with reductions in cornstarch intake lasting up to 5 years, what are the long-term implications of DTX401 treatment for GSDIa patients?
Added By: catalin_adminWith plans to discuss these Phase 3 results with regulatory authorities to support a marketing application, what are the key milestones and challenges in bringing DTX401 to market?
Added By: catalin_adminUltragenyx is committed to following patients for at least 10 years post-DTX401 infusion. What additional data do you hope to gather from this long-term follow-up, and how might it influence future research and treatment strategies for GSDIa and other similar conditions?
Added By: catalin_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
